PECIPTA 2009 : SILVER MEDAL

CONGRATULATIONS !!!

CONGRATULATIONS to Dr. Amin Malik Shah Abdul Majid, Hayder B. Sahib, Prof. Zahri Ismail, Dr. Salizawati M. Salhimi, Dr. Zaini Asmawi, M. Jamshed Siddiqui, and Khalid Hussin. Of course, not forgetting, Abdalrahim F.A. Aisha, Saleh Mustafa Al-Omari, and Norshirin Idris. 

The team won silver for product , Canssufive which is an inhibitor of angiogenesis and enhancer of Tamoxifen activity.

PECIPTA 2009 was held at KLCC on 8-10 October 2009 and was organized by Universiti Malaya. It was an annual  high profile Malaysia research exhibition where participants come from institutions of higher learning inside and outside of Malaysia.

AbdalRahim F. A. Aisha

A Lil Bit About Me:

Abdalrahim was born and grew up in small village near Nablus city of Palestine. His Bachelor’s degree was in Medical Laboratory Analysis in 1997 and his Master’s degree was in Biological Sciences in 2002 and both were obtained from An Najah National University of Palestine. He was working six years from 2002 to 2008 as a teacher in governmental section in Palestine. Since June 2008 he is enrolled in PhD programme at Department of Pharmacology, School of Pharmaceutical Sciences, USM. His research area is cancer therapeutics from natural products and especially from medicinal plants. His principal goal is to find a potent and coast effective anticancer drug from medicinal plants. He realized that a researcher life is his life and so he devoted most of his time for his research. He likes cooking especially Barbeque. Here he enjoys the beautiful nature of Malaysia with his beloved wife and his daughters Marah and Jana.

Research interests:

I'm interested in studying the anti-angiogenic activity of low molecular weight natural products for the treatment of different kinds of cancer. Besides that, I’m also want to explore the potential of natural products that I selected as anti-androgens and anti-estrogens for the treatment of both prostrate and breast cancers respectively.

[Contact]

PRESS CONFERENCE : CANSSUFIVE

The press conference was held on  21 October 2009, Wednesday at 11 am at Level 6 Canselory Building at the Universiti Sains Malaysia, Penang Campus.

 

EMAN group of researchers  has succeeded in producing standardised “Misai Kucing” (Orthosiphon Stamineus) herbal extract for the treatment of cancer.This novel  herbal extract is presented in the form of a pill is called CANSSUFIVE. Our group, headed by Dr. Amin Malik Shah has found out that Misai Kucing (literally meaning, Cat”s Whiskers), has high anti-oxidant content that could prevent and control the growth of cancer cells. 

“CANSSUFIVE shows very promising results in breast cancer treatment when given together with chemotherapy,”- Dr. Amin Malik Shah bin Abdul Majid

Dr. Amin said, the Misai Kucing extract named “CANSSUFIVE” was tested on animals and found to retard blood vessel development, thus preventing the cancel cells from spreading to tissues and other organs. He also planned to do clinical study on the effectiveness of Canssufive on humans as soon as possible so that cancer patients and others can get it on the market.

Nahdzatul Syima Binti Muslim

 A Lil Bit About Me:

Syima was born in Alor Star, Kedah in 8th of May 1985; where her family was living back then, before they moved to Kulim due to her mother and father’s work. She happily enjoyed her small town life in Kulim until she completed her high school days in Sekolah Menengah Kebangsaan Sultan Badlishah, Kulim in 2002. Then she continued to study Industrial Chemistry (Diploma) in Universiti Teknologi MARA, Perlis (a small state, yet a great place for cheap but yummy delicacies, lots of places to tour in with unique culture blending in and not to mention the chance to cross the border to Thailand!) until she graduated in September 2006. She went to study for bachelor degree in Applied Chemistry in Universiti Teknologi MARA, Shah Alam (the capital of Selangor with attracting shopping malls, near to KL, Klang, pricey food though) until she graduated in November 2008. Currently she’s a M.Sc student under the supervision of Dr. Amin Malik Shah Abdul Majid and her work involves bacterial work in which she is keen to study the expression of IFN – α in E. coli strains. The production of interferons shall be upscaled using our own 3-L biofermentor. The medium to be used will also be replaced with non – animal based medium. Previously during her undergraduates’ days, Syima had experiences of working with HPLC for her final year thesis. Apart from that, she also had experiences of working with AAS, UV-Vis and GC. Syima enjoys gardening around her family house, playing with her cats, playing games, watching movies and listening to music to fill in her free time. Syima is now residing in Seberang Jaya, Pulau Pinang with her family.


Research Interest:

I’m interested in expressing interferon – α using E. coli as the host and cloning the protein so that greater amount of the protein can be produced using a biofermentor. In order to do so, we need to setup the most suitable operating conditions, so that to ensure highest yield and purity of protein can be achieved. The media that will be used in the study will also be replaced with non – animal based media. In this study, interferons is the proteins of interest because interferons generally have the potential of anti – viral, anti – tumor and immunomodulatory activities, which in turn will enables them to be used as therapeutic agents (Nagamine et al, 2009). For these reasons, we are interested in expressing the stated protein, so that if we are capable to produce the product in greater amount, it might have potential to be combined with other kind of drugs to serve as therapeutic agents. We are also interested in optimizing the operating conditions of the biofermentor since it affect cell cultivation performance, and also gene expression. The knowledge of the biofermentor can then be applied in cultivating other types of cells in future.

[Contact]

BIOREACTOR TRAINING

On 6th and 7th of August 2009, a workshop on Bioreactor Operation was held in Physiology Teaching Laboratory, School of Pharmaceutical Sciences, Universiti Sains Malaysia. The workshop was organized by Pharmacology and Physiology Department, School of Pharmaceutical Sciences; USM in collaboration with Intran Technologies Sdn. Bhd. Intran Technologies Sdn. Bhd. is the company who supplied and maintained the bioreactor unit owned by the school.

15 participants whom were postgraduate students from School of Pharmaceutical Sciences, School of Biological Sciences, INFORMM and also Malaysian Institute of Pharmaceuticals and Nutraceuticals (iPHARM) participated in the two days workshop. In addition, there were 5 staffs from Intran Technologies Sdn. Bhd., who joined the workshop. The facilitator of the workshop was Mr. Mohd Rizal, a bioprocess expert from Universiti Putra Malaysia.

The workshop conducted involved lectures of theories and explanation regarding the bioreactor unit and components and their respective functions. The facilitator also conducted the workshop in laboratory session, to give deeper explanation about the bioreactor unit and its components to the participants, so as to increase participants’ understanding regarding the theories given in lectures. The facilitator did also show the basic operation of the bioreactor unit during the laboratory session. The bioreactor unit used in this workshop was of 3L working capacity. The bioreactor unit used as the model for this workshop is the unit which is currently located in Immunopharmacology Laboratory (J02-119).

-written by Syima-

Dr. Amin Malik Shah Bin Abdul Majid

Lecturer

School of Pharmaceutical Sciences, Universiti Sains Malaysia

Minden, 11800 Penang, Malaysia

Tel: 604-6577888 Ext. 4582

Email: : aminmalikshah@usm.my

Fax: 604-6570017

Education:

BSc.(Auckland),PGDip.Sci.(Auckland) M Sc. (UNSW,Aus.), Ph D. (UNSW,Aus.)

Discipline:

Pharmacology

Research Interest:

Cancer is fatal disease that is affecting one in every five Malaysians. The treatment success varies considerably with early detection being the most important factor. Chemotherapy is the mainstay for cancer treatment but it can cause adverse side effects and is highly unaffordable particularly the more modern drugs. The main aim of our research activity is to find cheap anti-tumor agents that also have fewer side effects.

We are interested in natural products that cause inhibition in blood vessel development, a process commonly referred as antiangiogenesis. This process is vital for tumor growth and is the key step for metastasis. Antiangiogenic agents are generally non-cytotoxic hence have fewer side effects. One of the emerging techniques in treating cancer is to couple antiangiogenic agents with classical chemotherapy. This has shown marked improvement in prolonging survival of cancer patients. The new antiangiogenic drugs however, are unaffordable to the general public. With the aid of the NaPIMM molecular modeling software package developed in USM by Habibah Wahab and coworkers, our team identified a series of plants that have compounds which can target the VEGFR2 receptor, a key receptor in angiogenesis pathway. By using an ex-vivo 3-Dimensional tissue culture technique, we screened standardized extracts of the potential plant short listed in NaPIMM for any antiangiogenic activity. We identified Bitter melon, Nutmeg and Misai Kucing to be amongst the most active plant species. We were able to distinguish the solvent system that gave the strongest response and the optimum dose required. We are currently co-administering classical chemotherapy agents with these extracts to see any synergistic activity in vitro and in vivo tumor models. We are also interested in looking at the genes that are being perturbed by co-administration of these extracts with classical chemotherapy drugs in the angiogenesis and carcinogenesis pathways. In the out set of this work, we are interested in how chemotherapeutic agents interact with the nucleic acid. By employing mass spectrometry machines, we are able to pin point the exact location of drug binding on the DNA. This information helps us to better design chemotherapeutic agents that interact with the DNA in a more sequence specific manner. We are currently developing a peptide based molecule that targets the hypoxic responsive element which activates VEGF. We hope this molecule is able to demonstrate potent antiangiogenic response.

Muath Hekmat Helal

A Lil Bit About Me :

Muath was born and grew up in small village surrounded by olive and orange trees named Qalqilia, Palestine. He graduated form Pharmacy school from the An-Najah National university in 2007. He joined Pharmacology department at Universiti Sains Malaysia in 2007 under the supervision of Dr. Amin Malik Shah Abdul Majid. During his master work, he had to work with different techniques and machines such as spectroscopy, cytotoxicity, and angiogenesis. He was more interested furthering his studies, therefore he proceeded with his master directly after graduation. He was awarded a scholarship from Malaysian Government during his Master studies. His research area is in Cancer pharmacology and focused on DNA and DNA-binding agents for treatment. Here, he lives happily in lovely-flat nearby in Penang.

Research Interest:

I am interested in studying DNA binding compounds. My main purpose for these is cancer treatment, but keeping in mind viral treatment as well. For the past several decades DNA has been the main target for cancer treatment. Unfortunately, these compounds tend to cause side effects including cancer. The main reason for causing side effects is the lack of sequence selectivity. These compounds do not have the ability to discriminate between DNA sequences. I am interested in studying the mechanism of how these compounds tend to bind with DNA in order to modify or synthesis new compounds that would have better sequence specificity. I am also interested in gene therapy as a potential cancer treatment method. Although peptide compounds might have better selectivity, it is known to have some difficulties in administering the products to human body.

[Contact]

Norshirin binti Idris

Research Interest:

Development of tumors is a highly complex process in which several molecular events are required for tumor cells to achieve independent growth. One such event is the enhancement of angiogenesis. Angiogenesis is the formation and growth of new blood vessels. It occurs in the healthy body for healing wounds and for restoring blood flow to tissues after injury or insult. Therefore angiogenesis is a necessary component of normal tissue repair, tumor growth and a wide variety of other inflammatory and pathological process as well. The normal healthy body maintains a perfect balance of angiogenesis modulators. For this reason, antiangiogenic therapies aimed at halting new blood vessel growth are being developed to treat diseases that involves angiogenesis such as cancer, diabetes retinopathy and rheumatism to name a few.

Mixtures of interacting compounds produced by plants may provide important combination therapies that concurrently have an effect on multiple pharmacological targets and provide clinical effectiveness beyond the reach of single compound-based drugs. The chemotherapeutic agents can be combined with botanical therapeutics, the plant-produced compounds which are used to treat and prevent diseases or maintain health and wellness.

Mitragyna speciosa or locally known as ketum was found to contain various alkaloids which makes it useful in the treatment of hypertension and boost the immune system. It was also found to contain some antioxidant compounds, which usually tend to have antiangiogenic properties. From the molecular modeling packages, the results showed that the plant product exhibits the antiangiogenic activity. For that reason, my work is to prove that the plant product is antiangiogenic and if so, to determine the mechanism that synergize the activity on how these extracts would be beneficial to perturb tumor growth.

[Contact]

Zena A. Abdul Hameed

Research Interest:

My project about the benzimidazole derivatives and their anticancer activity. As we know that the benzimidazole had wide biological activities like anti-inflammatory, antibacterial, antihypertensive and others. Also it’s well known anticancer agents due to their good topoisomerase I inhibiting action and DNA binding activity. DNA-topoisomerases are enzymes present in the nuclei of cells where they catalyze the breaking and rejoining of DNA strands hence controlling the topological state of DNA. Recent studies also suggest that topoisomerases are involved in regulating template supercoiling during RNA transcription. The antitumor activity associated with agents which are topoisomerase poisons is associated with their ability to stabilize the enzyme-DNA cleavable complex. This will prevent DNA proliferation which is an important stage in the growth of the cancer cells.

[Contact]

Nozlena Binti Abdul Samad

A Lil Bit About Me:

Nozlena Binti Abdul Samad was born on August 8 in Penang , Malaysia.She is the youngest child in a family of three. She happily lived in Bayan Lepas,Penang until finishing her High School.She had her early education at Sungai Ara Primary School and her secondary education (high school) at the Sungai Ara Secondary School.She did her Diploma in Science, Uitm in year 2004, Malaysia and received her BSc (Hons) in Biohealth from UM, Malaysia in year 2007. Currently she is registered to receive her Master degree from Advanced Medical and Dental Institute, USM. The title of her research is “Anti-angiogenic properties of Labisia pumila and its components”. Her research is being supervised by Dr Gurjeet Kaur a/p Chatar Singh (AMDI), Dr Amin Malik Shah Abd Majid (School of Pharmaceutical Sciences) and Dr Tan Mei Lan (AMDI ), Universiti Sains Malaysia. Her research area is in molecular pharmacology. Topics of M.Sc , posters and as well as her oral presentation , reflect her work and involvement in various techniques and machine handling such as angiogenesis , basic cell culture, media preparation, culturing techniques , cell maintenance, cytotoxicity , apoptosis and spectroscopy machine (Fourier Transform Infrared Spectroscopy,Gas Chromatography-Mass Spectroscopy). She was a recipient of the Academic Staff Training Scheme (ASTS) Scholarship.

ANNOUNCEMENT

1. 22 October 2009 

[read more]

Researches

SERVICES

Oncology Services

1. Xenograft model

2. In vivo target inhibition model

EMAN provides state-of-the-art preclinical xenograft models with multiple cell lines to support preclinical research and assessment of anticancer drugs. Our expert scientific staffs possess strong technical and academic backgrounds. With our new and complete laboratory facilities, validated xenograft models and supporting studies, EMAN is able to support a complete discovery and development program for anti-cancer drugs. We have established multiple in vitro and in vivo assay systems to evaluate novel anti-cancer compounds. Each assay is designed to understand specific aspects of drug property and its mechanism of action. By accessing our comprehensive capability, our customers can advance development programs in a timely and cost-effective manner. EMAN scientists have extensive experience with the design and execution of efficacy studies for all types of experimental cancer therapeutic agents including both small molecules and biologics. Our current cancer pharmacology service portfolio includes:

Human Xenograft Model

Human xenograft models are generated by inoculating a tumour cell lines into an immunodeficient rodent such as nude mice. This is a subcutaneous xenograft models. This model involves implantation of tumour cells via subcutaneous injection into the flank of nude mice. This model provides consistent and reproducible cell growth and permits easy access to the tumour for treatment and calliper measurement. We offer traditional subcutaneous models and other models and can customize models to meet a sponsor’s needs.

Human Tumour Cell lines available at EMAN are as follows-

Typical Study Parameters we evaluate at EMAN:

1. Human tumour cells grown in culture (ATCC or custom lines)

2. Cell implant subcutaneously into immuno-compromised animals

3. Tumours measured during growth phase

4. Animals treated with vehicle, test article, and positive controls

5. Various protocol-specified parameters/markers assessed ex vivo or in vivo assays

6. Report preparation.

EMAN scientific teams not only investigate the effect of test article on tumour growth but also actively participate in investigating the mode of action. In PK/PD studies the tumours are excised from the test article treated mice group along with respective control groups. Then the effect of test article at molecular level is investigated in different cell based assays. The MTD of the compound is also analysed.

EMAN follows the ASTM Testing Methods

ASTM F813 Direct Contact Cell Culture Evaluation of Materials for Medical Devices

TEAM MEMBERS

Principal Investigator:

Dr. Amin Malik Shah Bin Abdul Majid








PhDs:




Masters:

Zena A. Abdul Hameed

Norshirin binti Idris

Nozlena binti Abdul Samad

Muath Hekmat Helal

FACILITIES

CONTACT US

 Dr. Amin Malik Shah bin Abdul Majid
School of Pharmaceutical Sciences, Universiti Sains Malaysia
Minden, 11800 Penang, Malaysia
Tel: 604-6577888 Ext. 4582
Email: : aminmalikshah@usm.my
Fax: 604-6570017

COLLABORATIONS

under contrastruction.

PUBLICATIONS

2009

1. H.B., Sahib, A.F. Aisha, M.F. Yam, M.Z. Asmawi and Z. Ismail et al., 2009. Anti-angiogenic and anti oxidant properties of Orthosiphon stamineus benth. Methanolic leaves extract. Int. J. Pharmacol., 5: 162-167.
   

2. Sahib, H.B., Z. Ismail, N.H. Othman and A.M.S. Abdul Majid, 2009. Orthosiphon stamineus benth. methanolic extract enhances the anti-proliferative effects of tamoxifen on human hormone dependent breast cancer. Int. J. Pharmacol., 5: 273-276.
   

3. Aisha, A.F.A., Sahib, H.B., K.M. Abu-Salah, Y. Darwis and A.M.S. Abdul Majid, 2009.Cytotoxic and anti-angiogenic properties of the stem bark extract of sandoricum koetjap. Int. J. Cancer Res.( In Press)
   

4. A.F.A. Aisha, S.A. Alrokayan, K.M. Abu-Salah, Y. Darwis and A.M.S. Abdul Majid, 2009. In vitro Cytotoxic and Apoptotic Properties of the Stem Bark Extract of Sandoricum koetjape on Breast Cancer Cells, Int. J. Cancer Res.( In Press)
   
   

ABOUT EMAN

EMAN Research Laboratory is located in the School of Pharmaceutical Sciences, University Science Malaysia on the island of Penang.

EMAN focuses on early discovery of compounds that have potential anti-cancer activity and agents that perturb the angiogenesis pathways. The latter has wide variety of disease application including rheumatoid arthritis, diabetic blindness; age related macular degeneration, obesity, Alzheimer and cancer.

 EMAN provides testing services for in vitro and in vivo tumor and angiogenesis model as a proof of concept for test compound pharmacological activity validation. The testing facility includes a 2000 sq ft state-of-the are clean room facility that improves the quality of the testing services.

EMAN aims to provide its services to the local industries in Malaysia to facilitate the development of new drugs. EMAN also provides in vitro testing services for cytotoxic testing and mutagenicity testing according to ASTM methods.

TEAM MEMBERS

THE BIG BOSS


THE SECERTARY


DOCTORATES




MASTERS